PAHC vs. BSX

In the year-to-date period, PAHC achieves a 7.54% return, which is significantly lower than BSX's 15.16% return. Over the past 10 years, PAHC has underperformed BSX with an annualized return of -2.81%, while BSX has yielded a comparatively higher 19.59% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Phibro Animal Health Corporation (PAHC) and Boston Scientific Corporation (BSX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current PAHC Sharpe Ratio is 0.65, which is lower than the BSX Sharpe Ratio of 1.76. The chart below compares the historical Sharpe Ratios of PAHC and BSX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

PAHC's dividend yield for the trailing twelve months is around 2.14%, while BSX has not paid dividends to shareholders.

The maximum PAHC drawdown since its inception was -79.60%, smaller than the maximum BSX drawdown of -89.15%. Use the drawdown chart below to compare losses from any high point for PAHC and BSX. For additional features, visit the drawdowns tool.

This section allows you to compare key financial metrics between Phibro Animal Health Corporation and Boston Scientific Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.